Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Recent & Breaking News (NDAQ:HALO)

Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028

PR Newswire August 15, 2022

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028

PR Newswire August 15, 2022

HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS

PR Newswire August 9, 2022

Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer

PR Newswire August 2, 2022

Halozyme to Report Second Quarter 2022 Financial and Operating Results

PR Newswire July 26, 2022

Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

PR Newswire June 8, 2022

Halozyme Announces Commercial Launch of TLANDO(TM), an Oral Treatment for Testosterone Replacement Therapy

PR Newswire June 7, 2022

Halozyme Completes Antares Pharma Acquisition

PR Newswire May 24, 2022

Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma

PR Newswire May 12, 2022

Halozyme Reports First Quarter 2022 Results

PR Newswire May 10, 2022

Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call

PR Newswire May 3, 2022

HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA

PR Newswire April 26, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Antares Pharma, Inc. Buyout

Newsfile April 18, 2022

SHAREHOLDER ALERT: Weiss Law Investigates Antares Pharma, Inc.

PR Newswire April 13, 2022

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader

PR Newswire April 13, 2022

Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology

PR Newswire March 24, 2022

Positive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod Using ENHANZE® Drug Delivery Technology for Generalized Myasthenia Gravis

PR Newswire March 22, 2022

Halozyme Appoints Moni Miyashita to Board of Directors

PR Newswire March 15, 2022

HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS

PR Newswire February 22, 2022

HALOZYME TO HOST FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL

PR Newswire February 9, 2022